Literature DB >> 16378557

Developing an evidence base for intermediate care delivered by GPs with a special interest.

David Kernick, Russell Mannion.   

Abstract

Mesh:

Year:  2005        PMID: 16378557      PMCID: PMC1570510     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  6 in total

1.  Evidence based policy: proceed with care.

Authors:  N Black
Journal:  BMJ       Date:  2001-08-04

Review 2.  Using research to inform quality programmes.

Authors:  John Ovretveit; David Gustafson
Journal:  BMJ       Date:  2003-04-05

3.  Developing intermediate care provided by general practitioners with a special interest: the economic perspective.

Authors:  David P Kernick
Journal:  Br J Gen Pract       Date:  2003-07       Impact factor: 5.386

4.  Intermediate care.

Authors:  David Pencheon
Journal:  BMJ       Date:  2002-06-08

5.  The role of UK general practitioners with special clinical interests: implications for policy and service delivery.

Authors:  Andrew Nocon; Brenda Leese
Journal:  Br J Gen Pract       Date:  2004-01       Impact factor: 5.386

6.  Randomised controlled trial to compare GP-run orthopaedic clinics based in hospital outpatient departments and general practices.

Authors:  Richard Baker; Jo Sanderson-Mann; Stephen Longworth; Rachel Cox; Clare Gillies
Journal:  Br J Gen Pract       Date:  2005-12       Impact factor: 5.386

  6 in total
  3 in total

1.  No more neurophobia: welcome neurology in general practice.

Authors:  Leone Ridsdale
Journal:  Br J Gen Pract       Date:  2009-08       Impact factor: 5.386

2.  Patient pressure for referral for headache: a qualitative study of GPs' referral behaviour.

Authors:  Myfanwy Morgan; Linda Jenkins; Leone Ridsdale
Journal:  Br J Gen Pract       Date:  2007-01       Impact factor: 5.386

3.  An audit of orthopaedic referrals via Multi-Professional Triage Teams.

Authors:  B A Rogers; C Kabir; N Bradley
Journal:  Ann R Coll Surg Engl       Date:  2008-09-15       Impact factor: 1.891

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.